| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
1 company
M33 Growth I L.P. is Director at TOI.
Our model assigns M33 Growth I L.P. a below-average insider score of 23/100, based on 3 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -58.9%.
M33 Growth I L.P. has 5 Form 4 filings on record from March 2025 to November 2025, all as Director at Oncology Institute (TOI), 2025.
The 11 reported transactions were 6 open-market sales, 3 other transactions, 1 stock award and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $28.4M.
The largest open-market sale was 6,700,000 shares of TOI at an average $3.09 on September 4, 2025, about $20.7M.
None of the 3 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2025 | TOI Oncology Institute, Inc. | Director, 10% Owner | Sell | 6,700,000 | $3.09 | $20,703,000.00 | -91.9% | -5.8% | - | |
| Jun 5, 2025 | TOI Oncology Institute, Inc. | Director, 10% Owner | Sell | 750,000 | $3.05 | $2,287,500.00 | -37.1% | +15.8% | +74.6% | |
| May 20, 2025 | TOI Oncology Institute, Inc. | Director, 10% Owner | Sell | 2,000,000 | $2.71 | $5,425,800.00 | -59.7% | +45.3% | +43.2% |